DelveInsight’s, “Heart Failure Pipeline Insight 2024” report provides comprehensive insights about 75+ companies and 90+ pipeline drugs in the Heart Failure pipeline landscape. It covers the pipeline drug profiles, including Heart Failure clinical trials and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore our latest breakthroughs in Heart Failure Research. Learn more about our innovative pipeline today! @ Heart Failure Pipeline Outlook
Key Takeaways from the Heart Failure Pipeline Report
- In October 2024:- Pfizer- The primary purpose of this study is to assess the effect of repeated subcutaneous administration of ponsegromab (PF-06946860) compared to placebo on frequency, severity, and burden of symptoms as well as physical limitations in participants with heart failure and different ranges of circulating GDF-15 concentrations. The study will also assess the safety, tolerability, PK, PD, and immunogenicity of ponsegromab.
- In October 2024:- Regeneron Pharmaceuticals- A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of a Single Dose of REGN5381, an NPR1 Monoclonal Antibody Agonist, in Patients With Chronic Heart Failure With Reduced Ejection Fraction.
- In October 2024:- Boehringer Ingelheim- This study is open to adults aged 18 or above legal age with heart failure. People can join the study if they have heart failure symptoms and a left ventricular ejection fraction (LVEF) of 40% or more. The purpose of this study is to find out whether BI 690517 in combination with empagliflozin helps people with heart failure.
- DelveInsight’s Heart Failure Pipeline report depicts a robust space with 75+ active players working to develop 90+ pipeline therapies for Heart Failure treatment.
- The leading Heart Failure Companies includes Zensun (Shanghai) Sci & Tech, Windtree Therapeutics, TreeFrog Therapeutics, Torrent Pharmaceuticals, Tenaya Therapeutics, Tasly Pharmaceuticals, Sulfagenix, Stealth BioTherapeutics, SQ Innovation, Shanghai Hongyitang Biopharmaceutical Technology, scPharmaceuticals, Sardocor, Sana Biotechnology, Salubris Biotherapeutics, Roche, Rivus Pharmaceuticals, Ribomic, Renova Therapeutics, Relaxera, Regeneron Pharmaceuticals, Recardio, Quantum Genomics, Procella Therapeutics, Precigen, Pfizer, Paradigm biopharmaceuticals, Palatin Technologies, Orizuru Therapeutics, Olatec Therapeutics, Novo Nordisk, Metcela, Mesoblast Inc., Merck & Co, Lexicon Pharmaceuticals, Janssen Research & Development, Ionis Pharmaceuticals, InvivoSciences, Intra-Cellular Therapies, Innolife, Imbria Pharmaceuticals, Imara Inc, Hyloris Pharmaceuticals, Help Therapeutics, Heartseed, HAYA Therapeutics, GlaxoSmithKline, GB Sciences, Fujifilm Corporation, Evotec SE, Eli Lilly and Company, Edgewise Therapeutics, DiNAQOR, Cytokinetics, CUORiPS, Chong Kun Dang, Cardurion Pharmaceuticals, Cardiora, Cardior Pharmaceuticals, Cardiol Therapeutics, CardioCell, Bristol-Myers Squibb, Bristol Myers Squibb, Boryung Pharmaceutical, BlueRock Therapeutics, BioCardia, BIAL, Berlin Cures, BenevolentAI, Bayer, Athersys, AstraZeneca, Asklepios Biopharmaceutical, Antlia Biosciences, AnaCardio, AliveGen, Actelion Pharmaceuticals, and others.
- Promising Heart Failure Pipeline Therapies include CXL-1020, Strata 1 CXL-1020, Ularitide, Allogeneic Mesenchymal Bone Marrow Cells (aMBMC), Lactated Ringer’s Solution, Bisoprolol, Empagliflozin, Lixivaptan, and others.
Stay informed about the cutting-edge advancements in Heart Failure Treatments. Download for updates and be a part of the revolution in cancer care @ Heart Failure Clinical Trials Assessment
Heart Failure Emerging Drugs Profile
- Rexlemestrocel-L: Mesoblast
Revascor consists of 150 million mesenchymal precursor cells (MPCs) administered by direct injection into the heart muscle in patients suffering from CHF and progressive loss of heart function. MPCs release a range of factors when triggered by specific receptor-ligand interactions within damaged tissue. Based on preclinical data, it is believed that these factors induce functional cardiac recovery by simultaneous activation of multiple pathways, including induction of endogenous vascular network formation, reduction in harmful inflammation, reduction in cardiac scarring and fibrosis, and regeneration of heart muscle through activation of tissue precursors. Enrollment of 566 patients has been completed in a placebo-controlled Phase III trial to evaluate a single dose of Revascor in Class II/III CHF patients across multiple sites in North America. Patients with advanced heart failure constitute the majority of the patients enrolled in this clinical trial program. Currently, the drug is in Phase III stage of its development for the treatment of heart failure.
- HU 6: Rivus Pharmaceuticals
HU6 is a controlled metabolic accelerator (CMA) that provides a novel, measured approach to activating proton leak and mitochondrial uncoupling, a natural process in the body that regulates and dissipates energy. By ferrying protons out of the mitochondrial intermembrane space, CMAs cue the increased oxidation of sugars and fats, while maintaining the same baseline production of adenosine triphosphate (ATP). Activating this process results in the reduction of accumulated fat throughout the body. Currently, the drug is in Phase II stage of its development for the treatment of heart failure.
- HS-001: Heartseed Inc
HS-001, is allogeneic iPSC-derived, highly purified ventricular cardio myocyte spheroids. By forming micro-tissue-like spheroids, retention rate and viability of cell transplant are improved. The spheroids are transplanted using a special administration needle (SEEDPLANTER®) and guide adapter developed for the administration of the spheroids into the myocardial layer of the heart. The expected mechanism of action is that the transplanted cardio myocytes electrically couple with the patient’s myocardium to improve cardiac output by remuscularisation, and secretion of angiogenic factors to form new blood vessels around the transplant site (neovascularization). In June 2021, Heartseed and Novo Nordisk entered into global collaboration and license agreement for stem cell-based therapy for heart failure. Currently, the drug is in Phase I/II stage of its development for the treatment of heart failure.
- Ribonucleotide reductase based gene therapy: StemCardia
Ribonucleotide reductase based gene therapy is a novel investigational product candidate being developed by StemCardia. The drug candidate is based on Gene transference and Ribonucleotide reductase modulators mechanism of action. Currently, the drug is in preclinical stage of its development for the treatment of heart failure.
Learn more about Heart Failure Drugs opportunities in our groundbreaking Heart Failure Research and development projects @ Heart Failure Unmet Needs
Heart Failure pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.
- Oral
- Intravenous
- Subcutaneous
- Parenteral
- Topical
Heart Failure Products have been categorized under various Molecule types such as
- Recombinant fusion proteins
- Small molecule
- Monoclonal antibody
- Peptide
- Polymer
- Gene therapy
Discover the latest advancements in Heart Failure Treatment by visiting our website. Stay informed about how we’re transforming the future of Oncology @ Heart Failure Market Drivers and Barriers, and Future Perspectives
Scope of the Heart Failure Pipeline Report
- Coverage- Global
- Heart Failure Companies- Zensun (Shanghai) Sci & Tech, Windtree Therapeutics, TreeFrog Therapeutics, Torrent Pharmaceuticals, Tenaya Therapeutics, Tasly Pharmaceuticals, Sulfagenix, Stealth BioTherapeutics, SQ Innovation, Shanghai Hongyitang Biopharmaceutical Technology, scPharmaceuticals, Sardocor, Sana Biotechnology, Salubris Biotherapeutics, Roche, Rivus Pharmaceuticals, Ribomic, Renova Therapeutics, Relaxera, Regeneron Pharmaceuticals, Recardio, Quantum Genomics, Procella Therapeutics, Precigen, Pfizer, Paradigm biopharmaceuticals, Palatin Technologies, Orizuru Therapeutics, Olatec Therapeutics, Novo Nordisk, Metcela, Mesoblast Inc., Merck & Co, Lexicon Pharmaceuticals, Janssen Research & Development, Ionis Pharmaceuticals, InvivoSciences, Intra-Cellular Therapies, Innolife, Imbria Pharmaceuticals, Imara Inc, Hyloris Pharmaceuticals, Help Therapeutics, Heartseed, HAYA Therapeutics, GlaxoSmithKline, GB Sciences, Fujifilm Corporation, Evotec SE, Eli Lilly and Company, Edgewise Therapeutics, DiNAQOR, Cytokinetics, CUORiPS, Chong Kun Dang, Cardurion Pharmaceuticals, Cardiora, Cardior Pharmaceuticals, Cardiol Therapeutics, CardioCell, Bristol-Myers Squibb, Bristol Myers Squibb, Boryung Pharmaceutical, BlueRock Therapeutics, BioCardia, BIAL, Berlin Cures, BenevolentAI, Bayer, Athersys, AstraZeneca, Asklepios Biopharmaceutical, Antlia Biosciences, AnaCardio, AliveGen, Actelion Pharmaceuticals, and others.
- Heart Failure Pipeline Therapies- CXL-1020, Strata 1 CXL-1020, Ularitide, Allogeneic Mesenchymal Bone Marrow Cells (aMBMC), Lactated Ringer’s Solution, Bisoprolol, Empagliflozin, Lixivaptan, and others.
- Heart Failure Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
- Heart Failure Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
For a detailed overview of our latest research findings and future plans, read the full details of Heart Failure Pipeline on our website @ Heart Failure Drugs and Companies
Table of Content
- Introduction
- Executive Summary
- Biliary Tumor: Overview
- Pipeline Therapeutics
- Therapeutic Assessment
- Biliary Tumor– DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- Rilvegostomig: AstraZeneca
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- SHR-A1811: Jiangsu HengRui Medicine
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- AMG 193: Amgen
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- Drug name: Company name
- Drug profiles in the detailed report…..
- Inactive Products
- Biliary Tumor Key Companies
- Biliary Tumor Key Products
- Biliary Tumor- Unmet Needs
- Biliary Tumor- Market Drivers and Barriers
- Biliary Tumor- Future Perspectives and Conclusion
- Biliary Tumor Analyst Views
- Biliary Tumor Key Companies
- Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/